PR Newswire
LAS VEGAS, March 12, 2026
The endometriosis market is expected to grow steadily over the forecast period (2026-2036), driven by rising disease awareness, improving diagnosis rates, and advancements in noninvasive diagnostic approaches. Furthermore, the introduction of novel therapeutic options such as HMI-115 (Bayer/Hope Medicine), Merigolix/TU2670 (Tiumbio), Linzagolix (Kissei Pharmaceutical), Vipoglanstat (Gesynta Pharma), Estelle (Mithra Pharmaceuticals), VR103 (VaRi Bioscience), and others is anticipated to address longstanding unmet needs.
LAS VEGAS, March 12, 2026 /PRNewswire/ — Recently published Endometriosis Market Insights report includes a comprehensive understanding of current treatment practices, endometriosis emerging drugs, market share of individual therapies, and current and forecasted market size from 2022 to 2036, segmented into leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].
https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg
Endometriosis Market Summary
- The total endometriosis treatment market size is expected to grow positively by 2036 in the leading markets.
- The United States accounted for the largest endometriosis treatment market size in 2025, compared to other major markets, including the EU4 countries (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
- In 2025, the US reported ~7 million prevalent cases of endometriosis, a number expected to grow by 2036.
- Leading endometriosis companies, such as Bayer, Hope Medicine, Tiumbio, Kissei Pharmaceutical, Gesynta Pharma, Mithra Pharmaceuticals, VaRi Bioscience, and others, are developing new endometriosis treatment drugs that can be available in the endometriosis market in the coming years.
- The promising endometriosis therapies in clinical trials include HMI-115, Merigolix/TU2670, Linzagolix, Vipoglanstat, Estelle, VR103, and others.
Discover global endometriosis treatment market size and CAGR @ https://www.delveinsight.com/sample-request/endometriosis-market
Key Factors Driving the Growth of the Endometriosis Market
- Rising Endometriosis Prevalence: The rising prevalence of endometriosis is the primary strength of its global market, leading to more focus by pharmaceutical firms
- Advancements in Early Diagnostic Techniques for Endometriosis: New diagnostic tools and techniques or methods can be explored for the early detection of endometriosis in the affected patient pool
- Launch of Emerging Endometriosis Drugs: The dynamics of the endometriosis market are expected to change in the coming years, owing to the launch of emerging therapies such as HMI-115 (Bayer/Hope Medicine), Merigolix/TU2670 (Tiumbio), Linzagolix (Kissei Pharmaceutical), Vipoglanstat (Gesynta Pharma), Estelle (Mithra Pharmaceuticals), VR103 (VaRi Bioscience), and others.
Ramandeep Singh, Senior Consultant, Forecasting and Analytics at DelveInsight, said that the anticipated launch of novel therapies by key players during the forecast period (2026-2036) is expected to positively influence the endometriosis market in the US, driven by the development of safer, disease-modifying treatments with improved pain management.
Endometriosis Market Analysis
- There is no existing cure for endometriosis. Because symptoms can begin as early as a patient’s first menstrual period, managing the condition can span decades, including the years when many people hope to become pregnant.
- Current treatment options include off-label use of oral contraceptives, progestins as the primary medical therapy, and GnRH agonists or antagonists as secondary options. However, GnRH-based treatments induce a low-estrogen state and can cause significant adverse effects such as medication-induced menopause and bone loss. Notably, all of these therapies prevent conception while they are being used.
- In the United States, approved treatments include elagolix (marketed as ORILISSA) for endometriosis-related pain, as well as combination hormone therapies such as relugolix with estradiol and norethindrone acetate (marketed as MYFEMBREE).
- Several new therapies, such as HMI-115 (Bayer/Hope Medicine), Merigolix/TU2670 (Tiumbio), Linzagolix (Kissei Pharmaceutical), Vipoglanstat (Gesynta Pharma), Estelle (Mithra Pharmaceuticals), VR103 (VaRi Bioscience), and others, are currently in different stages of clinical development.
Endometriosis Competitive Landscape
Some of the endometriosis drugs under development include HMI-115 (Bayer/Hope Medicine), Merigolix/TU2670 (Tiumbio), Linzagolix (Kissei Pharmaceutical), Vipoglanstat (Gesynta Pharma), Estelle (Mithra Pharmaceuticals), VR103 (VaRi Bioscience), and others.
Bayer/Hope Medicine’s HMI-115 is a novel monoclonal antibody designed to block the prolactin receptor, a central driver of both the formation and maintenance of endometriosis. Prolactin signaling is known to promote lesion growth, inflammation, and pain. By inhibiting this receptor, HMI-115 seeks to reduce endometriosis-related pain and slow lesion development without relying on hormonal suppression.
Tiumbio’s TU2670 is an orally administered small-molecule GnRH receptor antagonist that lowers estradiol levels by directly binding to GnRH receptors in the pituitary gland. In contrast to injectable GnRH agonists, which cause deep, menopause-level hormonal suppression and can lead to bone loss and reduced patient comfort, TU2670 allows adjustable, therapeutic-range hormone reduction. This approach aims to maintain effectiveness while minimizing hypoestrogenic side effects and offers greater convenience through oral dosing. A Phase IIa clinical study is currently underway across five European countries to assess TU2670’s safety and its ability to relieve endometriosis-associated pain.
Gesynta Pharma is developing vipoglanstat (GS-248), a selective and potent inhibitor of the enzyme mPGES-1. This enzyme plays a crucial role in inflammatory processes and has been specifically linked to endometriosis pathology.
VaRi Bioscience’s VR103 vaginal ring provides a continuous release of progestin for three months and is intended to serve as an optimal first-line treatment for endometriosis. Its effectiveness is comparable to that of GnRH agonists and antagonists, but without reducing estrogen levels enough to affect bone mineral density. Its safety and tolerability profile surpasses that of existing progestin-only therapies, with minimal to no estrogen-withdrawal symptoms such as hot flashes, night sweats, vaginal dryness, or mood changes.
The anticipated launch of these emerging therapies are poised to transform the endometriosis market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the endometriosis market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.
Discover more about best-selling endometriosis drugs @ Endometriosis Drugs
Recent Developments in the Endometriosis Market
- In December 2025, Hope Medicine reported that its lead pipeline product, HMI-115, received FTD from the US FDA for the treatment of moderate to severe pain associated with endometriosis.
- In October 2025, Hope Medicine announced the successful completion of a global Phase II trial of HMI-115, a potential first-in-class monoclonal antibody. The company plans to initiate Phase III studies to further assess efficacy and safety in women with moderate to severe endometriosis-associated pain.
- In September 2025, Gesynta Pharma AB announced that its clinical trial application for the company’s Phase II trial of vipoglanstat for the treatment of endometriosis had been approved by the UK authorities. The clinical trial, named NOVA, intends to evaluate the efficacy and safety of vipoglanstat against placebo in approximately 190 patients with endometriosis across several European countries.
- In March 2025, TiumBio’s partner Hansoh Pharma expanded Merigolix (HS-10518) development to include Assisted Reproductive Technology (ART), broadening its therapeutic scope beyond endometriosis.
What is Endometriosis?
Endometriosis is a chronic condition in which tissue similar to the lining of the uterus begins to grow outside the uterus, often on the ovaries, fallopian tubes, or other pelvic organs. These abnormal growths respond to hormonal changes during the menstrual cycle, causing inflammation, scarring, and sometimes the formation of cysts. Because this tissue cannot exit the body during menstruation, it can lead to severe pelvic pain, heavy periods, pain during intercourse, and sometimes fertility challenges. Although endometriosis is long-term, its symptoms can be managed through medical treatments, lifestyle adjustments, and, in some cases, surgery.
Endometriosis Epidemiology Segmentation
The endometriosis epidemiology section provides insights into the historical and current endometriosis patient pool and forecasted trends for the leading markets. In the US, diagnosed prevalent cases of endometriosis are predominantly managed by gynecologists, accounting for about 3 million cases in 2025 and generalists represent the second-largest prescriber group, managing roughly 500,000 cases in 2025.
The endometriosis treatment market report proffers epidemiological analysis for the study period 2022-2036 in the leading markets, segmented into:
- Prevalent Cases of Endometriosis
- Diagnosed Prevalent Cases of Endometriosis
- Age-specific Diagnosed Prevalent Cases of Endometriosis
- Stage-specific Diagnosed Prevalent Cases of Endometriosis
- Prescriber Pattern-specific Diagnosed Prevalent Cases of Endometriosis
- Treated Cases of Endometriosis
Endometriosis Market Report Metrics
Details
Study Period
2022-2036
Coverage
7MM [The United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].
Endometriosis Epidemiology Segmentation Prevalent Cases of Endometriosis, Diagnosed Prevalent Cases of Endometriosis, Age-specific Diagnosed
Prevalent Cases of Endometriosis, Stage-specific Diagnosed Prevalent Cases of Endometriosis, Prescriber
Pattern-specific Diagnosed Prevalent Cases of Endometriosis, and Treated Cases of Endometriosis
Key Endometriosis Companies Bayer, Hope Medicine, Tiumbio, Kissei Pharmaceutical, Gesynta Pharma, Mithra Pharmaceuticals, VaRi Bioscience,
AbbVie, Myovant, Pfizer, and others
Key Endometriosis Therapies HMI-115, Merigolix/TU2670, Linzagolix, Vipoglanstat, Estelle, VR103, ORILISSA, MYFEMBREE/RYEQO, and others
Scope of the
Endometriosis
Market Report
- Therapeutic Assessment: Endometriosis current marketed and emerging therapies
- Endometriosis Market Dynamics: Key Market Forecast Assumptions of Emerging Endometriosis Drugs and Market Outlook
- Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
- Unmet Needs, KOL’s views, Analyst’s views, Endometriosis Market Access and Reimbursement
Download the report to understand top endometriosis therapies and market trends @ Endometriosis Market Analysis
Table of Contents
1
Endometriosis Market Key Insights
2
Endometriosis Market Report Introduction
3
Endometriosis Market Overview
3.1 Market Share (%) Distribution of Endometriosis by Therapies in the US
in 2025
3.2 Market Share (%) Distribution of Endometriosis by Therapies in the US
in 2036
4
Methodology of Epidemiology and Market
5
Executive Summary
6
Key Events
7
Disease Background and Overview
7.1
Introduction
7.2
Causes
7.3
Pathophysiology
7.4
Symptoms
7.5
Diagnosis
7.6
Treatment and Management of Endometriosis
8
Epidemiology and Patient Population
8.1
Key Findings
8.2
Assumptions and Rationale: The US
8.2.1
Prevalent Cases of Endometriosis
8.2.2
Diagnosed Prevalent Cases of Endometriosis
8.2.3
Age-specific Diagnosed Prevalent Cases of Endometriosis
8.2.4
Stage-specific Diagnosed Prevalent Cases of Endometriosis
8.2.5 Prescriber Pattern-specific Diagnosed Prevalent Cases of
Endometriosis
8.4
The US
8.4.1
Prevalent Cases of Endometriosis
8.4.2
Diagnosed Prevalent Cases of Endometriosis
8.4.3
Age-specific Diagnosed Prevalent Cases of Endometriosis
8.4.4
Stage-specific Diagnosed Prevalent Cases of Endometriosis
8.4.5 Prescriber Pattern-specific Diagnosed Prevalent Cases of
Endometriosis
8.4.6
Total Treated Cases of Endometriosis
8.5
EU4 and the UK
8.6
Japan
9
Endometriosis Patient Journey
10
Marketed Endometriosis Therapies
10.1
Key Cross Competition
10.2
ORILISSA (elagolix): AbbVie
10.2.1
Product Description
10.2.2
Regulatory Milestone
10.2.3
Other Developmental Activities
10.2.4
Clinical Trials Information
10.2.5
Safety and Efficacy
10.3 MYFEMBREE/RYEQO (relugolix, estradiol, and norethindrone acetate):
Myovant/Pfizer
List to be continued in the report…
11
Emerging Endometriosis Therapies
11.1
Key Cross Competition
11.2
HMI-115: Bayer/Hope Medicine
11.2.1
Drug Description
11.2.2
Other Developmental Activities
11.2.3
Clinical Trials Information
11.2.4
Safety and Efficacy
11.2.5
Analyst Views
11.3
Merigolix/TU2670: Tiumbio/ Hansoh Pharma
List to be continued in the report…
12
Endometriosis: Market Analysis
12.1
Key Findings
12.2
Key Endometriosis Market Forecast Assumptions
12.3
Attribute Analysis
12.4
US Endometriosis Market Outlook
12.5
Total Market Size of Endometriosis in the US
12.6
Market Size of Endometriosis by Therapies in the US
12.7
EU4 and the UK Endometriosis Market Outlook
12.8
Japan Endometriosis Market Outlook
13
Key Opinion Leaders’ Views on Endometriosis
14
Endometriosis Market SWOT Analysis
15
Endometriosis Market Unmet needs
16
Endometriosis Market Access and Reimbursement
17
Bibliography
18
Acronyms and Abbreviations
19
Endometriosis Market Report Methodology
Related Reports
Endometriosis Clinical Trial Analysis
Endometriosis Pipeline Insight – 2026 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key endometriosis companies, including Hope Medicine Inc, Gesynta Pharma AB, Changchun GeneScience Pharmaceutical Co., Ltd., TiumBio, Jiangsu Hengrui Medicine Co, EpicentRx, NETRIS Pharma, Maipl Therapeutics, Temple Therapeutics, Cartherics Pty Ltd, among others.
Endometriosis Pain
Market
Endometriosis Pain
Market Insights, Epidemiology, and Market Forecast
–
2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key endometriosis pain companies including Horizon Therapeutics (Amgen), Dompe Farmaceutici, Sylentis, MorphoSys, Resolve Therapeutics, OSE Immunotherapeutics, Servier, Novartis, Johnson & Johnson, among others.
Endometriosis Pain Clinical Trial Analysis
Endometriosis Pain Pipeline Insight – 2026 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key endometriosis pain companies, including Ferring Pharmaceuticals, ObsEva SA, Myovant Sciences, Hope Medicine (Nanjing) Co., Ltd, TiumBio Co., Ltd., Mitsubishi Tanabe Pharma, among others.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Contact Us
Shruti Thakur [email protected] +14699457679www.delveinsight.com
Logo: https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/endometriosis-market-expected-to-achieve-significant-cagr-during-the-forecast-period-20262036-driven-by-innovative-treatment-options–delveinsight-302711899.html
Tengo varias preguntas sobre esto a ver si me podiais aclarar:
-¿Puedo hacer un ingreso regular de 800 euros y me cobran 0euos de comisiones y mto.?
-¿Puedo sacar el dinero cuando quiera?,¿todo ó tengo entendido que hay que mantener un mínimo de 100 euros los 30 meses?
-No necesito pero me obligan a sacar una tarjeta de débito que me cuesta 11 euros el primer año y 22 euros la renovación, también otra de credito que me cuesta 0 euros el primer año y 35 euros la renovación.
¿Hay que mantenerlas 13 meses?
¿Puedo cancelar alguna de ellas desde el principio?
¿Puedo cancelar alguna de ellas antes de la renovación?
¿Hay alguna tarjeta de credito más barata?
Aparte de la cuenta nómina he visto que también que para que te den la tv también se puede sacar una cuenta tarifa plana básica o personal, ¿sabeis algo de estas cuentas?¿que requisitos tienen?
Muchas gracias a todos por responder
Yo fui a informarme y te cuento. Únicamente admiten los ingresos regulares en el caso de que seas autónomo. Te abren una cuenta Tarifa Plana Cero que está exenta de comisiones y presenta alguna ventaja más. Sobre dejar un mínimo de saldo en la cuenta no es necesario, pero sí te obligan a mantener varias tarjetas durante los 30 meses con un coste aproximado de 100 euros anuales.
hola buenas!
me llamo javi y estoy dudando de que banco, me puede dar mas beficios, sin sorpresas por domiciliar la nomina, ya que llevo años en la caixa y no me da nada ningun beneficio. es mas me rechazan los prestamos que solicito, ni siquiera una targeta de credito, por alegan de que siempre esta a cero la cuenta, yo cuando cobro la nomina dejo el dinero para los pagos, y saco el resto, pues no me fio, de que un dia me quede sin dinero, ya que esta todo muy mal, corre riesgo mi dinero o mis ahorros en el banco?? muchas gracias y un cordial saludo.
javi
NO TE EXTRAÑE QUE NO TE DEN LOS PTMOS, PORQUE LO QUE VEN ES QUE NO TIENES CAPACIDAD DE AHORRO PORQUE SIEMPRE DEJAS LA CTA. EN MINIMOS, ASI NINGUN BANCO TE LO VA A CONCEDER. TAMBIEN ES VERDAD QUE LA CAIXA, COMO TANTAS OTRAS CAJAS, TIENE EL PUÑO CERRADO PARA LOS RIESGOS, PARA REMONTAR. NO TE PREOCUPES, QUE POR UNA NOMINA NO CREO QUE NINGUN BANCO SE COJA LAS MANOS. LOS QUE SE TIENEN QUE PREOCUPAR SON LOS QUE TIENEN DÉPÓSITOS Y FONDOS EN BANCOS DE DUDOSA ACTIVIDAD. LA GENTE SE PIENSA QUE PORQUE LES DEN UN 7% YA ES UN GRAN BANCO Y SE EQUIVOCAN. LO QUE LES PASA ES QUE EL BANCO DE ESPAÑA LES PRESTA EL DINERO MAS CARO Y POR ESO OPTAN POR CONSEGUIRLO EN EL MERCADO MONETARIO, Y SI EL BANCO DE ESPAÑA NO SE FIA DE ELLOS, VA Y SE FIA LA GENTE. QUE LOS BANCOS NOES LA ADMON PUBLICA, ABRAN OS OJOS.
Hola , cuando vallais al banco queos dejen lo que hay que pagar de irpf y de iva sobre el valor de la tele ya que en la mayoria de bancos esto no lo dicen y luego llagan las sorpresas .A mi ya me ha pasado con la promoción del portatil y nunca me hablaros de esto . Cuidado
Yo he estado calculando y la tele entre unas cosas y otras te sale sobre unos 250euros que tampoco regalan tanto .Hay oficinas en las que han dado la occión de poner un dinero a plazo fijo a 12meses de 9300euros o 6800euros a 18 meses.
No es ningún chollo. Te obligan a contratar dos tarjetas de crédito que tienes que pagar porque las tienes que mantener 13 meses por lo menos y además llevan unos costes desproporcionados si las utilizas. En total, no usando las tarjetas y anulándolas una vez cumplidos los 13 meses puedes ahorrar unos 38 euros con respecto al precio de ese televisor en una gran superficie. Y además luego vendrá que te cobran para hacienda la retención correspondiente, por lo que probablemente incluso en las mejores condiciones te cueste más que si ahorras un poco y lña compras directamente.
Creó que teneis toda la razón, que aqui no te regalan nada, ya que a mí me paso con unas sartenes que regalaban el banco bilbao, que al final entre el irpf y el descuento de Hacienda, al final me salieron caras, así es que no os tomen el pelo, que al final siempre esta la letra pequeña que es la que nos joroba, por no decir otra cosa.
Yo saque el portatil y ahora me he sacado la TV LCD 32. Estas promos no hay que declararlas. No es obligado domiciliar nomina. Si, meter en la cuenta 800€ todos los meses en un margen de 10 dias. Cero matacero, pero cero,cero, cero de gastos de mantenimiento, ni por recibos, ni por el correo a casa, ni por transfer. Las tarjets gratis el 1er año. Resto fuera. Dadas de baja Menos la de debito. Banesto no pierde nada, ganar, gana clientes que es el proposito de esta promo. Precio de portatil y tv 32 en mercao unos 900€ los 2. En banest 197€. Los hay mejores, nos ha jodio! portatiles a 1200€, TV LCD 32 a 1000€. Señores, son lentejas. Relacion calida-precio-promo es cojonud…….Un saludit a los viandantes.
hola , no se si llegara mi comentario pero os voi a esplicar. esto es el cuento de la abuela. mira yo tengo el portatil. y he cogio tab la tele, pero sabeis ke?, me ha pasado de todo. os esplico. primero me cobran 74 euros y 25 euros de unas tarjetas que yo no las he visto aparecer por mi casa , me cabreo con el banco. llamo y pido esplicaciones. me dicen que van en la promocion, nunca jamas nadie me informo de las tarjetas, no me devuelven el dinero. me cabreo y me dicen que llame aun numero de tefono para darlas de baja, se pasan los dias, intentamos darlas de baja. largas y larga, que si este numero de tefono que si el otro bla bla bla. conseguimos hablar y nos dicen que tenemos que cambiar el contrato a tarifa plana o no se ke historias, llamando al banco se pasan los dias, largas y largas. me cabreo y estoi por suspender todo, me dicen que si lo quiero cambiar y dar de baja las tarjetas que nunca he tenido. tengo que pagar comisiones cada seis meses de doce y pico euros, y que si no quiero que me cobren comisiones tengo que ir todos los meses al banco a hacerlo yo, ufffffffffff.aun hay mas. me dan de baja y me hacen la tarifa plana, se equivocan un monton de veces. me hacen pasar muchos cabreos.y al final cuando llego a casa me han cobrado 25, 50 euros. y llamo por telefono y se lo digo , me dicen claro por dar de baja la otra cuenta , la madre que los pario. ladrones. o sea os digo que la tele no sale regalada, se la cobran y muy bien cobrada , nadie da nada por nada. en cuento termine de pagar lo que debo quito todas las cuentas del banesto.espero que alguien me lea y que me conteste gracias .
Banesto ha jodido a mi marido y a un amigo tambien. Para mi, despues de Banco de Andalucía son los peores. Y quieran creerlo o no ni la television ni el portátil te lo regalan.. como no cumplas cualquiera de las reglas te sancionan con 300 y pico de euros.. porque nos hemos mudado de casa y los recibos domiciados se cortaron «temporalmente» la sancion fue de mas de 300 euros.. y el cabreo q te llevas cuando ves lo q te han descontado y luego para ir a reclamarlos.. y como te tratan !! en fin.. espero que Banesto sea lo primero en undirse en el fin del mundo!!
CHOLLO!!!!!!!!!JAJAJAJAJA…….NO ES NINGUN CHOLLO!!!!!!! te cobran 100 € de gastos de manipulacion, mas 150 € en tarjetas durante 2 años, mas 6 € mensuales de mantenimiento de cuenta durante 30 meses, total que pagas 630 Euros por un ordenador o una TV que su valor seguro que no llega a 500 €. Y encima si vas a cancelar la cuenta cuando cumples los 30 meses requeridos te hacen esperar dos horas para decirte que no tienen linea de telefono para dar de baja la cuenta, cosa que no para nunca cuando vas a contratarlo. Y del trato que dispensan….., es el mismo que si vas con un fajo de billetes de 500 € por los CO-JONES
Banesto «premia», menuda falacia…
No hay ningún banco que premie a nadie.
BANESTO NECESITA NUESTRAS NÓMINAS, Y EN CUANTO VAS UN POCO JUSTO, COMO BUENOS JUDÍOS Y ÁVAROS QUE SON, TE ACOSAN Y MACHACAN, Y TE SACAN HASTA LAS ENTRAÑAS EN COMISIONES.
DESPUÉS EL ESTADO APOYA A LOS BANCOS, CON LA EXCUSA DE QUE SI CAEN LOS BANCOS CAEMOS TODOS. LOS BANCOS NECESITAN UN BOICOT DE VEZ EN CUANDO, PARA QUE NO NOS RESTREGUEN POR LA CARA SUS BENEFICIOS.
POR CIERTO, LO QUE MÁS FASTIDIA A UN BANCO ES UNA RECLAMACIÓN EN LA OFICINA DEL CONSUMIDOR Y OTRA AL BANCO DE ESPAÑA.
ES POR DAR PISTAS…